329328-49-6

Upstream product

• 149418-41-7 3,4-dibromo-2(5H)-furanone 
• 17113-79-0 trimethyl(4-(methylthio)phenyl)stannane 
• 98546-51-1 (4-thiomethoxyphenyl)boronic acid 

Downstream Products

• 162012-30-8 4-(4-(methylthio)phenyl)-3-phenylfuran-2(5H)-one 
• 162012-28-4 4-(4-(methylthio)phenyl)furan-2(5H)-one 
• 487047-31-4 3-chloro-4-(4'-methylsulfonylphenyl)-5H-furan-2-one 
• 745820-44-4 4-(4-(methylsulfinyl)phenyl)-3-phenylfuran-2(5H)-one 
• 866336-10-9 thiobutyric acid S-[4-(5-oxo-4-phenyl-2,5-dihydro-furan-3-yl)-phenyl] ester 
• 162011-90-7 rofecoxib 

Relevant academic research and scientific papers

Preparation of aryl-substituted butenolides using mucohalic acids

Methods and materials for preparing 3-aryl-2-buten-4-olides and 2,3-bisaryl-2-buten-4-olides are disclosed. The methods include reacting a mucohalic acid with a reducing agent to give a 2,3-dihalo-2-buten-4-olide, which undergoes at least one Pd catalyzed cross-coupling reaction with an arylboronic acid.

A general method for the synthesis of aryl [11C]methylsulfones: Potential PET probes for imaging cyclooxygenase-2 expression

A general one-pot method has been developed for the conversion of an aryl thiol moiety masked as the butyrate ester to the corresponding 11C-labeled methylsulfone group. The potential of this methodology has been demonstrated by the successful radiosynthesis of carbon-11 analogues of several highly selective cyclooxygenase-2 (COX-2) inhibitors such as Rofecoxib, Etoricoxib, and 3-(4-methylsulfonylphenyl)-4-phenyl-5-trifluoromethyl isoxazole in high yield. The chemical and radiochemical purities obtained for the 11C-labeled COX-2 inhibitors are >99% with a specific activity >1000 Ci/mmol.

Reinvestigation of mucohalic acids, versatile and useful building blocks for highly functionalized alpha,beta-unsaturated gamma-butyrolactones.

[reaction: see text] Mucohalic acids (mucochloric acid (1, 3,4-dichloro-5-hydroxy-5H-furan-2-one) and mucobromic acid (2, 3,4-dibromo-5-hydroxy-5H-furan-2-one)) are inexpensive, commercially available starting materials with multiple functional groups. These compounds have been modified by way of reduction followed by Suzuki cross-coupling reactions involving arylboronic acids to afford highly functionalized alpha,beta-unsaturated gamma-butyrolactones in excellent yield. The synthetic utility of these building blocks was effectively demonstrated through preparation of the antiinflammatory drug Vioxx.

Selective synthesis of (Z)-4-aryl-5-[1-(aryl)methylidene]-3-bromo-2(5H)-furanones

4-Aryl-3-bromo-2(5H)-furanones have been selectively synthesized in satisfactory yields by treatment of easily available 3,4-dibromo-2(5H)-furanone either with arylboronic acids in the presence of Ag2O and a catalytic amount of PdCl2(MeCN)2 or with aryl(trialkyl)stannanes in the presence of a catalyst precursor consisting of AsPh3 and a Pd(II) or a Pd(0) compound. These monobromo derivatives have been then used as precursors to a variety of (Z)-4-aryl-5-[1-(aryl)methylidene]-3-bromo-2(5H)-furanones including the compound with the structure corresponding to that reported for naturally occurring rubrolide N. The structure and stereochemistry of these synthetic compounds have been unambiguously established by NMR techniques.

Selective synthesis of unsymmetrical 3,4-disubstituted and 4-substituted 2(5H)-furanones

Easily available 3,4-dibromo-2(5H)-furanone undergoes regioselective palladium-catalyzed reaction with aryl(trialkyl)stannanes to give the corresponding 4-aryl-3-bromo-2(5H)-furanones in satisfactory yields. These monobromo derivatives have proven to be useful precursors to unsymmetrical 3,4-diaryl-2(5H)-furanones, 4-aryl-3-methyl-2(5H)-furanones and 4-aryl-2(5H)-furanones.